CAR T Cell Immunotherapy for Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Pancreatic CancerCancer of the Pancreas

Interventions

BIOLOGICAL

huCART-meso cells

Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.

Trial Locations (1)

University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

University of Pennsylvania

OTHER